The inspection concluded that no Form 483 had been issued. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25. Shares of Alkem Laboratories shed 0.97% to end at Rs 4,704.10 on Thursday, 13 March 2025.Powered by Capital Market - Live

The products will be available at prices approximately 80% lower than those of the innovator products. Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicated for the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD), and chronic heart failure (HF). Alkem's generic empagliflozin and its combinations are bioequivalent to the innovator products. Alkem's generic empagliflozin is available under the brand name Empanorm, and its combinations are as follows: (i) empagliflozin and linagliptin are available under the name Empanorm L; (ii) empagliflozin and sitagliptin are available under the names Empanorm Duo and Alsita E; and (iii) empagliflozin and metformin are available under the name Empanorm M. Dr. Vikas Gupta, chief executive officer, Alkem, said, 'As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone. This globally accepted molecule has transformed diabetes care with its additional benefits in managing chronic kidney disease and cardiovascular health. Leveraging Alkem's strong distribution network, we aim to make this therapy widely available, enhancing treatment accessibility and improving health outcomes for patients across the country. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit declined 1.8% to Rs 625.82 crore in Q3 FY25 as compared with Rs 637.37 crore in Q3 FY24. Net sales rose 1.5% YoY to Rs 3,374.28 crore in Q3 FY25. Shares of Alkem Laboratories shed 0.71% to Rs 4,742 on the BSE.Powered by Capital Market - Live

Alkem Laboratories announced the launch of generic empagliflozin and its combinations in India under the brand name 'Empanorm' at prices that are approximately 80% lower than the innovator products. Empagliflozin is an SGLT-2 (Sodium-Glucose Co-Transporter-2) inhibitor indicted for use in the treatment of type-2 diabetes mellitus, chronic kidney disease (CKD) and chronic heart failure (HF). Alkem's generic empagliflozin and its combinations are bioequivalent to innovator products. With a patient-centric approach, Alkem has introduced anti-counterfeit security band on the pack of Empanorm, as well as comprehensive patient education information, including basic details on diabetes management in Hindi and English with infographics, and QR codes that provide prescribing information and additional patient education information on diabetes, heart failure, and chronic kidney disease in 11 languages. Keeping patient-convenience in mind, Alkem is offering the medicine in a considerably smaller tablet size than the innovator products. Alkem's generic empagliflozin is available under the brand name 'Empanorm' and its combinations namely: (i) empagliflozin and linagliptin is available under the name 'Empanorm L'; (ii) empagliflozin and sitagliptin is available under the name 'Empanorm Duo' and 'Alsita E'; and (iii) empagliflozin and metformin is available under the name 'Empanorm M'. Powered by Capital Market - Live

Alkem Laboratories has appointed Shirish Purushotham Ambulgekar at senior management position in the Company effective from 10 March 2025. Shirish Purushotham Ambulgekar has completed his Masters of Science in Industrial Chemistry. He brings with him over 30 years of professional experience in the Indian pharmaceutical segment across uality assurance, corporate quality and quality control functions. Powered by Capital Market - Live

Net profit of Alkem Laboratories rose 5.19% to Rs 625.82 crore in the quarter ended December 2024 as against Rs 594.96 crore during the previous quarter ended December 2023. Sales rose 1.52% to Rs 3374.28 crore in the quarter ended December 2024 as against Rs 3323.87 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales3374.283323.87 2 OPM %22.5121.29 - PBDT816.35775.77 5 PBT731.07706.21 4 NP625.82594.96 5 Powered by Capital Market - Live

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 7 February 2025, inter alia, have recommended the interim dividend of Rs 37 per equity Share (i.e. 1850%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 5283.4, up 0.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.09% on the day, quoting at 23583.2. The Sensex is at 77886.15, down 0.22%. Alkem Laboratories Ltd has slipped around 5% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 4.11% in last one month and is currently quoting at 22009.05, up 0.26% on the day. The volume in the stock stood at 55658 shares today, compared to the daily average of 90616 shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 5265.1, up 0.59% on the day. Alkem Laboratories Ltd is down 0.52% in last one year as compared to a 8.59% jump in NIFTY and a 19.15% jump in the Nifty Pharma index.The PE of the stock is 29.06 based on TTM earnings ending September 24.Powered by Capital Market - Live

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live

The said transaction is part of the company's ongoing initiative of networking strategy and optimization of manufacturing facilities. The sale includes all rights, title and interest in the leasehold land, factory building, assets and liabilities etc. associated with the said facility. The business transfer agreement has been executed between the company and Rubicon Research on a slump sale basis. The company would receive a cash consideration of Rs 133.5 crore. Rubicon Research is engaged in the business of development, manufacture, distribution and sale of pharmaceutical formulations. Rubicon does not belong to the promoter/ promoter group of Alkem Laboratories. Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company's consolidated net profit jumped 11% to Rs 688.64 crore in Q2 FY25 as compared with Rs 620.52 crore in Q2 FY24. Net sales fell marginally 0.7% YoY to Rs 3414.67 crore in Q2 FY25. Powered by Capital Market - Live

Alkem Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 5567.2, up 1.54% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.04% on the day, quoting at 23803.900390625. The Sensex is at 78735.73, up 0.05%. Alkem Laboratories Ltd has slipped around 2.21% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 3.31% in last one month and is currently quoting at 23008.35, up 0.8% on the day. The volume in the stock stood at 1.05 lakh shares today, compared to the daily average of 1.21 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 5571.1, up 1.21% on the day. Alkem Laboratories Ltd is up 8.73% in last one year as compared to a 9.48% jump in NIFTY and a 37.57% jump in the Nifty Pharma index.The PE of the stock is 30.31 based on TTM earnings ending September 24.Powered by Capital Market - Live